National Institute for Health and Care Excellence technology appraisals (TA) for antivascular endothelial growth factor therapies
| Condition | Ranibizumab | Aflibercept |
| Neovascular age-related macular degeneration | Recommend 8/2008 (TA 155) | Recommend 7/2013 (TA 294) |
| Diabetic macular oedema | Reject 11/2011 (TA 237) Recommend 2/2013 (TA 274) | Recommend 7/2015 (TA 346) |
| Retinal vein occlusion | Recommend 5/2013 (TA 294) | Recommend 2/2014 (TA 305) |
| Myopic choroidal neovascularisation | Recommend 11/2013 (TA 298) | Recommend 9/2016 (TA 409) |